Latest Research Reports

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

A large number of clinical trials evaluating inhibitors of the enzyme poly ADP ribose polymerase (PARP) in breast and ovarian cancers are either ongoing or completed....

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

Targeted therapies will radically improve head and neck cancer treatment

Head and neck cancer (HNC) is the sixth most common cancer worldwide, and the majority of available treatments are highly toxic...

Targeted therapies will radically improve head and neck cancer treatment